Palatin Technologies, Inc. (PTN) AI Stock Analysis

Palatin Technologies, Inc. is a biopharmaceutical company based in Cranbury, New Jersey, focused on developing targeted receptor-specific therapies. Its primary focus is Vyleesi, a melanocortin receptor agonist approved for hypoactive sexual desire disorder in premenopausal women. The company is advancing oral PL8177, a selective MC1r agonist peptide that completed Phase I trials for inflammatory bowel diseases, and L8177, an oral peptide formulation in Phase 2 trials for ulcerative colitis. Additionally, Palatin is developing PL9643, a peptide agonist targeting ocular anti-inflammatory conditions such as dry eye disease, and PL3994, a peptide mimetic molecule.

Palatin reported revenue of $13.2M in FY2026, up 193.6% from $4.5M in FY2024. Despite this increase, the company recorded a net loss of -$8.4M in FY2026, compared to a net loss of -$29.7M in FY2024 and -$27.5M in FY2023. Operating margin improved to -65.7% in FY2026 from -501.0% in FY2024. For the latest quarter ended June 30, 2026, revenue fell 80.1% year-over-year, while trailing twelve-month revenue reached $13.2M with a net profit margin of -63.5%. R&D expenses totaled $12.4M in FY2026, down from $22.4M in FY2024.

As of June 30, 2026, Palatin held $7.5M in cash and short-term investments against total debt of $223,679, resulting in net cash of $7.3M. Shareholders' equity stood at $6.7M, supported by a current ratio of 4.61 and a debt-to-equity ratio of 0.03. Cash flow remains constrained, with FY2026 operating cash flow of -$13.5M and free cash flow of -$13.6M. Capital expenditures were $51,299 in FY2026, while the share count decreased 58.9% over the past five years.

At a last close of $6.02 on October 16, 2026, Palatin has a market cap of $10.7M and an enterprise value of $8.4M. The company trades at a forward P/E of 42.9x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio is 0.8x, below the US-listed Healthcare peer median of 4.1x, while its EV/EBITDA is 0.5x versus the peer median of 12.0x. Over the past year, PTN declined 15.2% while the S&P 500 gained 16.8%. Over five years, the stock dropped 98.9% versus an 83.0% gain for the S&P 500.

Wall Street sentiment includes 2 Strong Buy and 1 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target of $53.50 implies a 788.7% premium over the last close of $6.02. For the fiscal year ending June 30, 2027, consensus estimates project revenue of $8.6M and EPS of -$2.41. Palatin beat earnings expectations in 2 of the last 4 quarters, and its next earnings date is scheduled for November 13, 2026.

This page is an AI-written research summary of Palatin Technologies, Inc. (PTN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PTN income statement, PTN balance sheet, PTN key metrics, PTN analyst forecast, PTN chart. See the PTN stock overview for the latest quote and news.